Detalhe da pesquisa
1.
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
N Engl J Med
; 384(22): 2102-2114, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077643
2.
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Future Oncol
; 19(6): 413-426, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36919916
3.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
4.
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
Breast Cancer Res Treat
; 179(1): 161-171, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605311
5.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402321
6.
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Breast Cancer Res Treat
; 168(3): 631-638, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29280043
7.
Neoadjuvant therapy for breast cancer.
Annu Rev Med
; 66: 31-48, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25386936
8.
Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
Lancet Oncol
; 17(7): e294-e304, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27396647
9.
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.
Breast Cancer Res
; 16(1): 201, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25192370
10.
Personalized therapy for breast cancer: a dream or a reality?
Future Oncol
; 9(8): 1105-19, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23902243
11.
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Curr Opin Oncol
; 24(6): 612-22, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23014186
12.
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Curr Opin Oncol
; 24(6): 623-34, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22960556
13.
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Expert Opin Investig Drugs
; 31(6): 633-644, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35451891
14.
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.
Cancers (Basel)
; 14(15)2022 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35954426
15.
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638394
16.
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Clin Breast Cancer
; 20(2): 174-181.e3, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924513
17.
Anticancer drug development: moving away from the old habits.
Curr Opin Oncol
; 26(3): 334-9, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24614094
18.
Progress in adjuvant systemic therapy for breast cancer.
Nat Rev Clin Oncol
; 16(1): 27-44, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30206303
19.
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
Anticancer Res
; 39(2): 797-802, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30711959
20.
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Clin Cancer Res
; 24(13): 3079-3086, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29530933